Reliance Trust Co Of Delaware buys $4,168,323 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Reliance Trust Co Of Delaware scooped up 1,316 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 42,318 shares of Celgene Corporation which is valued at $4,168,323.Celgene Corporation makes up approximately 0.38% of Reliance Trust Co Of Delaware’s portfolio.

Other Hedge Funds, Including , Capital Advisors Ltd. added CELG to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $19,700. Celgene Corporation makes up approx 0.01% of Capital Advisors Ltd.’s portfolio.Howland Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 74,512 additional shares and now holds a total of 76,737 shares of Celgene Corporation which is valued at $7,722,044. Celgene Corporation makes up approx 0.73% of Howland Capital Management’s portfolio.Morgens Waterfall Vintiadis Co Inc reduced its stake in CELG by selling 26,000 shares or 46.43% in the most recent quarter. The Hedge Fund company now holds 30,000 shares of CELG which is valued at $3,049,200. Celgene Corporation makes up approx 2.75% of Morgens Waterfall Vintiadis Co Inc’s portfolio.E&g Advisors Lp boosted its stake in CELG in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 14,318 shares of Celgene Corporation which is valued at $1,492,938. Celgene Corporation makes up approx 0.88% of E&g Advisors Lp’s portfolio.

Celgene Corporation closed down -2.13 points or -2.12% at $98.5 with 43,17,515 shares getting traded on Friday. Post opening the session at $101.25, the shares hit an intraday low of $98.48 and an intraday high of $101.389 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.